Stay Informed on Key Developments

Investor News and Updates

Bill_Ipad

Stay informed about key developments at our company as they happen. Discover our Ad-Hoc Releases and subscribe to our newsletter to receive the latest news and topics of interest.

51 - 60of 392 News

51 - 60of 392 News

August 28, 2023

Not intended for UK Media

BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

August 24, 2023

Not intended for U.S. and UK Media

Additional studies with finerenone across a wide range of heart failure patients initiated

August 21, 2023

Heike Prinz appointed to Board of Management of Bayer AG

August 08, 2023

Bayer Group:

Second quarter impacted by declines in glyphosate business

July 24, 2023

Bayer lowers full-year outlook

June 29, 2023

Not intended for U.S. and UK Media

Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years

June 28, 2023

Not intended for U.S. and UK Media – Bayer Pharmaceuticals R&D Event 2023 for Investors:

Bayer’s new pharmaceutical R&D strategy to accelerate breakthrough innovations

June 28, 2023

Not intended for UK Media

BlueRock’s neuronal stem cell therapy for Parkinson’s disease is first to show positive results in Phase I clinical study

June 22, 2023

Not intended for U.S. and UK Media

Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes

June 20, 2023

Crop Science Innovation Summit 2023:

Bayer sees more than doubling of accessible markets and potential to shape regenerative agriculture on more than 400 million acres

Inform Yourself on Special Topics

Control Weeds Not Farming

Control Weeds, Not Farming

Farmers discussing their weed management

Everything You Need to Know About Glyphosate

some-bayer-group-headquarters

Managing Glyphosate Litigation

woman harvesting carrots

Managing and Mitigating PCB Litigation Risk